I-Mab Biopharma dosed its first patient in mainland China as part of its ongoing pivotal Phase II trial evaluating an experimental antibody therapy from Morphosys called MOR202 (TJ202) as a treatment for patients with relapsed or refractory multiple myeloma. This...